Celiac Disease Foundation congratulates Sheila E. Crowe, MD, FRCPC, FACP, FACG, AGAF of University of California, San Diego (UCSD), a member of our esteemed Medical Advisory Board, for her service as the 2017-2018 American Gastroenterological Association President. A clinician-scientist and Professor in the Division of Gastroenterology in the Department of Medicine at UCSD, Dr. Crowe is…

Launched in February 2016, iCureCeliac® is a free online portal for patients, or their caregivers, to provide critical insights into life with celiac disease and gluten/wheat sensitivity. Anonymized questionnaire data, completed by iCureCeliac® participants under informed consent, are made available to researchers and governmental policy analysts to advance life-changing initiatives. Your participation will help create better diagnostic tools and treatments…

The current standard for a celiac disease diagnosis is a positive blood test for specific antibodies, followed by a biopsy of the intestine that reveals damage to the villi (villous atrophy). These tests are certainly invasive and unpleasant, but more than that, they are useless in cases where a patient is already following a gluten-free…

Celiac Disease Found to Be Underfunded By NIH Compared to Other Diseases

ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease…

On November 4, 2016, Celiac Disease Foundation was invited to present a live session of the Celiac Disease Patient Advocacy Program at the Center for Celiac Research and Treatment 20th Anniversary Celebration and Symposium at Massachusetts General Hospital. CDF CEO, Marilyn Geller, and Communications Manager, Talia Hassid, educated a packed room of people about patient-centered…

Last month, we shared the statistics from the first 1,200 participants in iCureCeliac®. Our first cut of analysis revealed interesting and, quite frankly, potentially alarming numbers about celiac disease, such as: 33 percent of iCureCeliac® participants reported that diagnosis took longer than five years from the onset of their first symptoms. 53 percent of iCureCeliac®…

With more than 1,200 participants registered in its first four months, iCureCeliac™ is shaping the type of research that is most important to you - the patient. We are pleased to present a few initial findings.

Considering the rising number of cases of celiac disease, and its extremely detrimental effects on childhood development, leading to malabsorption and failure to thrive, it is becoming more necessary to find a means to properly diagnose young children.

Newly diagnosed patients with celiac disease were found to be at risk of metabolic syndrome and hepatic steatosis upon adopting a gluten-free diet. An in-depth nutritional assessment is recommended at diagnosis and during follow-up.